NT-proBNP/urine hepcidin-25 ratio and cardiorenal syndrome type 1 in patients with severe symptomatic aortic stenosis-Reference-Cited by-同舟云学术

NT-proBNP/urine hepcidin-25 ratio and cardiorenal syndrome type 1 in patients with severe symptomatic aortic stenosis

Published:2023-05 Issue:10 Volume:17 Page:475-485
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Nübel Jonathan¹,Hoffmeister Meike²³,Labrenz Oliver⁴,Jost Kerstin⁴,Oess Stefanie²³,Hauptmann Michael³⁵,Schön Julika⁶,Fritz Georg⁷,Haase Michael⁸⁹¹⁰,Butter Christian¹³,Haase-Fielitz Anja¹³¹⁰^ORCID

Affiliation:

1. Department of Cardiology, University Hospital Heart Centre Brandenburg & Faculty of Health Sciences Brandenburg, Brandenburg Medical School (MHB), Bernau, 16321, Germany

2. Institute of Biochemistry, Brandenburg Medical School (MHB), Brandenburg, 14770, Germany

3. Faculty of Health Sciences (FGW), Joint Faculty of the University of Potsdam, the Brandenburg Medical School & the Brandenburg Technical University Cottbus-Senftenberg, Cottbus, Germany

4. Department of Psychology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School (MHB), Neuruppin, 16816, Germany

5. Institute of Biostatistics & Registry Research, Brandenburg Medical School (MHB), Neuruppin, 16816, Germany

6. Anesthesia & Intensive Care, University Hospital Ruppin-Brandenburg, Brandenburg Medical School (MHB), Neuruppin, 16816, Germany

7. Department of Anesthesiology, Intensive Care & Pain Therapy, University Hospital Heart Centre Brandenburg, Brandenburg Medical School (MHB), Bernau, 16321, Germany

8. Diamedikum Kidney Care Centre, Potsdam, 14473, Germany

9. Department of Nephrology & Hypertension, Hannover Medical School, Hannover, 30625, Germany

10. Institute of Social Medicine & Health System Research, Otto von Guericke University Magdeburg, Magdeburg, 39120, Germany

Abstract

Background: This study aimed to determine whether novel and conventional cardiorenal biomarkers in patients before transcatheter aortic valve implantation may be associated with cardiorenal syndrome (CRS) type 1. Methods: Serum NT-proBNP and urine biomarkers (hepcidin-25, NGAL, IL-6) were measured before and 24 h after transcatheter aortic valve implantation. Results: 16/95 patients had CRS type 1. Those patients had longer length of stay in hospital (12.5 [9.0–16.0] vs 9.0 [8–12] days; p = 0.025) and were more frequently readmitted to hospital within 6 months after discharge (46.7 vs 15.6%; odds ratio: 4.7; 95% CI: 1.5–15.5; p = 0.007). The NT-proBNP/urine hepcidin-25 ratio (odds ratio: 2.89; 95% CI: 1.30–6.41; p = 0.009) was an independent modifier of CRS type 1. Conclusion: The NT-proBNP/urine hepcidin-25 ratio appears to be a modifier of risk of CRS type 1.

Funder

Funded by the Brandenburg Medical School (MHB) publication fund supported by DFG

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2023-0034

Reference37 articles.

1. Cardiorenal Syndrome

2. Change in Kidney Function and 2-Year Mortality After Transcatheter Aortic Valve Replacement

3. Characteristics and Outcomes of Patients With Aortic Stenosis and Chronic Kidney Disease

4. Cardiorenal Syndrome Type 1

5. Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)